The PITPNM1 antibody targets the PITPNM1 protein, a member of the membrane-associated phosphatidylinositol transfer protein (PITPNM) family. PITPNM1. also known as RDGBα or PYK2 N-terminal domain-interacting receptor, plays a critical role in intracellular lipid transport and signaling. It contains an N-terminal phosphatidylinositol transfer domain (PITP) and C-terminal repetitive domains, facilitating interactions with membranes and signaling molecules. PITPNM1 regulates phosphoinositide homeostasis, impacting processes like vesicular trafficking, cytoskeletal reorganization, and cell migration. Dysregulation of PITPNM1 is linked to cancer metastasis, neurodegenerative disorders, and metabolic diseases.
Antibodies against PITPNM1 are essential tools for studying its expression, localization, and function. They are widely used in techniques such as Western blotting, immunofluorescence, and immunohistochemistry to investigate its role in cellular pathways. Research highlights its involvement in growth factor signaling (e.g., EGFR, PDGFR) and interactions with Rho GTPases, influencing Golgi structure and cell motility. PITPNM1 antibodies also aid in exploring its potential as a biomarker or therapeutic target in diseases characterized by aberrant lipid signaling or membrane dynamics. Validated antibodies are critical for distinguishing PITPNM1 from homologous family members (PITPNM2/3) due to structural similarities. These reagents support ongoing studies in cancer biology, neurobiology, and metabolic regulation.